Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1493-1497

  Uncu, Dogan ^a   Ozdemir, Nuriye Yildirim ^a   Aksoy, Sercan ^a   Abali, Huseyin ^b   Oksuzoglu, Berna Cakmak ^a   Budakoglu, Burçin ^a   Yildiz, Ramazan ^c   Aslan, Nalan ^a   Zengin, Nurullah ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Adjuvant; Chemoradiotherapy; Cisplatin; Folinic acid; Gastric cancer

Indexed keywords

EID: 79956083421     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bajetta E, Buzzoni R, Mariani L, et al (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian trials in medical oncology (ITMO) group. Ann Oncol, 13, 299-307.
2. Beşe NS, Büyükünal E, Ozgüroǧlu M, et al (2005). Toxicity and survival results of a phase II study investigating the role of postoperative chemo-radioimmunotherapy for gastric adenocarcinoma. Strahlenther Onkol, 181, 652-9.
3. Bonenkamp JJ, Hermans J, Sasako M, et al (1999). Extended lymph-node dissection for gastric cancer. Dutch gastric cancer group. N Engl J Med, 340, 908-14.
4. Bouche O, Raoul JL, Bonnetain F, et al (2004). Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a federation francophone de cancerologie digestive group study- FFCD 9803. J Clin Oncol, 22, 4319-28.
5. Coombes RC, Schein PS, Chilvers CE, et al (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International collaborative cancer group. J Clin Oncol, 8, 1362-9.
6. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
7. Cuschieri A, Weeden S, Fielding J, et al (1999). Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical cooperative group. Br J Cancer, 79, 1522-30.
8. Earle CC, Maroun JA (1999). Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients. Revisiting a meta-analysis of randomized trials. Eur J Cancer, 35, 1059-64.
9. Faivre J, Forman D, Esteve J, et al (1988). Survival of patients with esophageal and gastric cancers in Europe. Eurocare working group. Eur J Cancer, 34, 2167-75.
10. Hallissey MT, Dunn JA, Ward LC, et al (1994). The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, 343, 1309-12.
11. Hundhal SA, Menck HR, Mensour EG, et al (1997). The national data base report on gastric carcinoma. Cancer, 80, 2333-41.
12. Hundhal SA, Phillips JL, Menck HR (2000). The national Cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American joint committee on cancer staging, proximal disease, and the "different disease" hypothesis. Cancer, 88, 921-32.
13. Kollmannsberger C, Budach W, Stahl M, et al (2005). Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol, 16, 1326-33.
14. Lise M, Nitti D, Marchet A, et al (1995). Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol, 13, 2757-63.
15. Louvet C, Andre T, Tigaud JM, et al (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20, 4543-8.
16. Macdonald JS, Fleming TR, Peterson RF, et al (1995). Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a southwest oncology group study. Ann Surg Oncol, 2, 488-94.
17. Macdonald JS, Smalley S, Benedetti J, et al (2001). Chemoradiation after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30.
18. Mari E, Floriani I, Tinazzi A, et al (2000). Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomized trias. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol, 11, 837-43.
19. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemoterapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
20. Ross P, Nicolson M, Cunningham D, et al (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 20, 1996-2004.
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol, 24, 4991-7.
22. Vanhoefer U, Wagener T, Lutz M, et al (2001). Randomized phase II study of weekly 24h infusion of high dose 5-FU ± folinic acid (HDFU ± FA) vs HD-5-FU/FA/biweekly cisplatin in advanced gastric cancer. Eur J Cancer, 37, (Abstr 88).
23. Zhang ZX, Gu XZ, Yin WB, et al (1998). Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys, 42, 929-34.